ANN ARBOR, Mich. & HENDERSON, Nev.–(BUSINESS WIRE)– #CHF–Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease, today announced they have entered into a definitive agreement for Esperion to acquire Corstasis. Under the terms of the agreement, Esperion will acquire Corstasis, which developed and is commercia